Effect of amiodarone on serum quinidine and procainamide levels.

  title={Effect of amiodarone on serum quinidine and procainamide levels.},
  author={Andres Saal and Jeffrey A. Werner and Harry L. Greene and Gena K. Sears and E L Graham},
  journal={The American journal of cardiology},
  volume={53 9},
Effect of amiodarone on the disposition of procainamide in the rat.
The data suggest that amiodarone interacts with procainamide by reduction of an alternate pathway of elimination, possibly oxidative metabolism.
Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide
It is indicated that amiodarone has pharmacokinetic and electrophysiologic interactions with procainamide and it is suggested that the intravenous dose of Procainamide be reduced by 20% to 30% during concurrent drug administration.
The Effect of Amiodarone on Theophylline Pharmacokinetics in the Rat
The data demonstrate an acute inhibitory effect of amiodarone on the hepatic microsomal enzyme system and theophylline, an investigational antiarrhythmic agent which has been implicated in reducing the activity of the hepatitis mixed-function oxidase system.
Amiodarone: Pharmacology and Antiarrhythmic and Adverse Effects
Due to ocular, dermatologic, gastrointestinal, neurologic, cardiovascular, thyroid and pulmonary toxicity, amiodarone should be reserved for use in patients with refractory and/or life‐threatening arrhythmias.
Pharmacokinetics of Quinidine in Male Patients
Improvement of the CL model by inclusion of measured AAG strongly suggests that quinidine elimination is dependent on the free concentration of drug in plasma and supports the use of free serum qu inidine concentrations when evaluating and monitoring quinazine therapy.
Pharmacokinetic Drug Interactions with Amiodarone
  • L. Lesko
  • Biology, Medicine
    Clinical pharmacokinetics
  • 1989
There is still a need for prospective controlled clinical studies to be conducted on many likely combinations of other drugs with amiodarone to increase understanding of the magnitude, time-course, mechanism and relevance of pharmacokinetic changes caused by this drug.
Effects of chronic treatment with amiodarone on hepatic demethylation and cytochrome P450
The discrepancy between its in‐vivo effects and cytochrome P450 levels may suggest the development of ‘compensatory’ extra‐hepatic site of drug metabolism.
Quinidine-Nifedipine Interaction
Clinicians should be alert to the possibility of an alteration in quinidine serum concentrations when instituting or discontinuing nifedipine in patients receivingQuinidine.


Amiodarone increases plasma digoxin concentrations.
It is observed that several patients receiving maintenance digoxin treatment abruptly developed clinical evidence of toxicity when amiodarone, a newly available antiarrhythmic agent, was administered in addition.
Amiodarone-induced ventricular fibrillation.
The risk of lethal arrhythmias is such that caution is required in its use and the suggestion that this drug may be given in large doses for long periods of time since it has a wide safety margin is felt to be correct.
Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias.
The potentiation of warfarin anticoagulation by amiodarone.
Amiodarone appears to augment the depression of vitamin K-dependent coagulation factors caused by warfarin by an uncertain mechanism, and may lead to serious bleeding.
Clinical efficacy of amiodarone as an antiarrhythmic agent.
Amiodarone-lnduced Ventricular Tachycardia
Excerpt Virtually all antiarrhythmic agents may facilitate ventricular tachycardia. However, amiodarone has been free of this adverse effect, except in two cases where it was used in combination wi...
Long‐term Management of Sustained, Recurrent, Symptomatic Ventricular Tachycardia with Amiodarone
The main advantages of amiodarone were prolonged duration of action (recurrences occurred only 15-60 days after the drug was discontinued or the dose lowered, virtual absence of contraindications, doses as high as 2000 mg/day were safe and patient compliance was excellent).
Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.
It is concluded that amiodarone is effective for long-term therapy of recurrent ventricular tachyarrhythmias, that induction of arrhythmia during therapy does not always predict efficacy, and that side effects are frequent but do not usually limit therapy.